



Synthesis and biological evaluation of novel thienopyrimidine derivatives as diacylglycerol acyltransferase 1 (DGAT-1) inhibitors

Dong Jin Hong, Seung Hyun Jung, Jisook Kim, Danbee Jung, Young Gil Ahn, Kwee Hyun Suh & Kyung Hoon Min

To cite this article: Dong Jin Hong, Seung Hyun Jung, Jisook Kim, Danbee Jung, Young Gil Ahn, Kwee Hyun Suh & Kyung Hoon Min (2020) Synthesis and biological evaluation of novel thienopyrimidine derivatives as diacylglycerol acyltransferase 1 (DGAT-1) inhibitors, *Journal of Enzyme Inhibition and Medicinal Chemistry*, 35:1, 227-234, DOI: [10.1080/14756366.2019.1693555](https://doi.org/10.1080/14756366.2019.1693555)

To link to this article: <https://doi.org/10.1080/14756366.2019.1693555>



© 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.



Published online: 22 Nov 2019.



[Submit your article to this journal](#)



Article views: 2560



[View related articles](#)



[View Crossmark data](#)



Citing articles: 8 [View citing articles](#)

SHORT COMMUNICATION



Synthesis and biological evaluation of novel thienopyrimidine derivatives as diacylglycerol acyltransferase 1 (DGAT-1) inhibitors

Dong Jin Hong^{a,b}, Seung Hyun Jung^b, Jisook Kim^b, Danbee Jung^a, Young Gil Ahn^b, Kwee Hyun Suh^b and Kyung Hoon Min^a

^aCollege of Pharmacy, Chung-Ang University, Seoul, Republic of Korea; ^bHanmi Research Center, Hanmi Pharm. Co., Ltd., Gyeonggi-Do, Republic of Korea

ABSTRACT

A novel series of thieno[3,2-*d*]pyrimidine derivatives were synthesised and their inhibitory effects against diacylglycerol acyltransferase 1 (DGAT-1) were assessed. *cis*-Isomer **17a** showed potent and selective inhibitory activity against DGAT-1 in SF9 cells. In addition, **17a** had an acceptable pharmacokinetic profile and accumulated mainly in the small intestine and liver. Oral administration of **17a** led to a significant reduction in plasma triacylglycerol level during an oral lipid tolerance test (OLTT) in murine and canine models. Taken together, **17a** is a high-quality candidate that deserves further investigation.

ARTICLE HISTORY

Received 25 September 2019
Revised 21 October 2019
Accepted 10 November 2019

KEYWORDS

DGAT-1; obesity; small molecules; thienopyrimidine; type 2 diabetes

Introduction

Obesity is characterised by abnormal fat accumulation due to a systemic dysfunction of energy homeostasis. It is a significant risk factor for diabetes, hypertension, cardiovascular disease, and non-alcoholic fatty liver disease¹. Excessive accumulation of triglycerides (or triacylglycerol, TAG) in adipocytes and non-adipocytes, including in the liver, skeletal muscle, myocardium, and pancreas, is a crucial feature of obesity². In particular, abnormal TAG levels increases the risk of metabolic syndrome, characterised by as insulin resistance, dyslipidemia and cardiomyopathy³.

Therefore, preventing excessive accumulation of TAG could be beneficial in the treatment of metabolic diseases such as obesity and type 2 diabetes. Two routes of TAG biosynthesis have been identified: the glycerol phosphate pathway, and the monoacylglycerol pathway⁴. Both routes have a common intermediate, diacylglycerol (DAG), which is then converted to TAG by acyl CoA: diacylglycerol acyltransferase (DGAT)⁵. DGAT exists as two isoforms, DGAT-1 and DGAT-2, which share minimal sequence homology⁶. These enzymes catalyse the final dedicated step in TAG synthesis: i.e. the esterification of a fatty acid moiety to DAG to generate TAG. DGAT-1 is highly expressed in the small intestine, adipose tissue, and liver⁶. DGAT-1 deficient mice showed a significant reduction in the postprandial increase of plasma TAG and were resistant to diet-induced obesity due to increased energy expenditure. Moreover, the *DGAT1* knockout mice had enhanced sensitivity to insulin and leptin. Indeed, DGAT-1 inhibitors had significant pharmacologic effects, including decreased TAG, which were consistent with the *DGAT1* knockout mice phenotypes⁷. However, *DGAT2* knockout mice had extremely low levels of TAG, and their skin could not protect against moisture, so these mice died after birth⁸. Therefore, selective DGAT-1 inhibitors have been developed to manage metabolic diseases such as obesity and type 2 diabetes^{9–11}. Pharmaceutical companies, including

AstraZeneca (**1**)¹², Novartis (**2**)¹³, Pfizer (**3**)¹⁴, and Abbott (**4**)¹⁵, and Hoffmann-La Roche (**5**)¹⁶ are developing selective DGAT-1 inhibitors, whose structures are described in Figure 1. Other novel DGAT1 inhibitors have also been reported^{17–19}.

Herein, we described the discovery of novel thieno[3,2-*d*]pyrimidine derivatives as DGAT-1 inhibitors. Target molecules were designed based on a bioisosteric replacement strategy (Figure 2). Introduction of a heterobicyclic instead of a phenyl linker was attempted. Thienopyrimidines showed various pharmacologic activities as a privileged scaffold²⁰, and the introduction of thieno[3,2-*d*]pyrimidine was the first approach to designing novel inhibitors based on the structural features of reported DGAT-1 inhibitors.

Materials and methods

Chemistry

All commercial chemicals and solvents were reagent grade and were used without further purification. Completion of the reactions was monitored by analytical thin layer chromatography (TLC) using precoated glass-backed plates (E-Merck, silica gel 60 F₂₅₄ 0.25 mm). For normal pressure and flash column chromatography purifications, Merck silica gel 60 (size 70–230 and 230–400 mesh, respectively) was used. ¹H and ¹³C NMR spectra were recorded with an Avance DPX-300 NMR spectrometer (Bruker, Germany) and Jeol 600 MHz spectrometer (Jeol Resonance ECZ 600 R, USA). All the ¹H and ¹³C NMR spectra were recorded in deuterated chloroform (CDCl₃) with tetramethylsilane (TMS) as an internal standard or deuterated dimethyl sulfoxide (DMSO)-*d*₆ as solvents; chemical shifts are reported in δ values (ppm) relative to the residual solvent peak. Multiplicity was indicated as follows: s (singlet); d (doublet); t (triplet); m (multiplet); dd (doublet of doublet);




Figure 1. (a) Structures of reported DGAT1 inhibitors; (b) diagram showing structural features of DGAT-1 inhibitors.




Figure 2. A schematic strategy for the design of target molecules.

brs (broad singlet). Mass spectra were obtained on Waters Aquity UPLC/QTOF (Waters Corporation, USA). HPLC was used Agilent, 1200 series using capcellpak MGII (4.6×150 mm, $5 \mu\text{m}$) eluted with a 30 min gradient from 20–70% acetonitrile in water.

Synthesis of 17a and 17b

Tert-butyl 4-(4-(7-bromothieno[3,2-*d*]pyrimidin-4-yl)phenyl)carbamate (8)

A mixture of 7-bromo-4-chlorothieno[3,2-*d*]pyrimidine **6** (13 g, 52.10 mmol, CY C37043, KindChem Corporation, China), *t*-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) phenylcarbamate **7** (20 g, 62.70 mmol), tetrakis(triphenylphosphine)palladium (3.16 g, 2.73 mmol) and sodium carbonate (8.28 g, 78.12 mmol) were added to 100 mL of 1,4-dioxane/water (4:1), and then stirred at 80 °C for 18 h under argon atmosphere. The organic layer was extracted with 300 mL of ethyl acetate and 300 mL of water, dried

over anhydrous magnesium sulphate, and then concentrated *in vacuo*. Subsequently, 30 mL of methanol was added, and the resulting mixture was stirred to precipitate out solids, and then filtered to obtain 12.5 g of the yellow title compound.

$^1\text{H-NMR}$ (300 MHz, CDCl_3): δ 9.80(s, 1H), 8.18(d, $J = 6.9$ Hz, 2H), 8.04(s, 1H), 7.62(d, $J = 6.9$ Hz, 2H), 6.76(s, 1H), 1.58(s, 9H).

Methyl 2-(4-(4-(4-((tert-butoxycarbonyl)amino)phenyl)thieno[3,2-*d*]pyrimidin-7-yl)cyclohex-3-en-1-yl)acetate (10)

A mixture of **8** (0.56 g, 1.38 mmol), 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)cyclohex-3-en-1-yl)acetate **9** (0.5 g, 1.78 mmol), which was prepared according to the reported method²¹, and tetrakis(triphenylphosphine)palladium (94.9 mg, 0.08 mmol) was added to a solution of 2.06 mL of 2 *N* aqueous sodium carbonate and 8.2 mL of 1,4-dioxane, and then stirred at 100 °C for 12 h under argon. The reaction mixture was extracted with 300 mL of ethyl acetate and 300 mL of water. The organic layer was dried

with anhydrous magnesium sulphate, filtered and then concentrated. Subsequently, methanol was added to the resulting solution, stirred to precipitate out solids, and then filtered to obtain 315 mg of the yellow title compound.

$^1\text{H-NMR}$ (300 MHz, CDCl_3): δ 9.30(s, 1H), 8.17(d, $J=8.7$ Hz, 2H), 7.43(s, 1H), 7.59(d, $J=8.7$ Hz, 2H), 7.16(bs, 1H), 6.69(s, 1H), 3.71(s, 3H), 2.64~2.38(m, 3H), 2.2 6~2.02(m, 6H), 1.56(s, 9H). LCMS (ESI) m/z 480.2 $[\text{M} + \text{H}]^+$; HRMS calcd for $\text{C}_{26}\text{H}_{29}\text{N}_3\text{O}_4\text{S}$ $[\text{M} + \text{H}]^+$ 480.1957, found 480.1986

Methyl 2-(4-(4-(4-(*t*-butoxycarbonyl)amino)phenyl)thieno[3,2-*d*]pyrimidin-7-yl)cyclohexyl) acetate (11)

To a solution of **10** (315 mg, 0.66 mmol) in ethanol (50 mL) and 1,4-dioxane (20 mL) was added 20% charcoal-shaped palladium hydroxide (158 mg, 50%w/w). The mixture was stirred at room temperature under H_2 overnight. The reaction mixture was filtered through Celite, and then the filtrate was concentrated to obtain the title compound **11** (190 mg), which was used in the following step without further purification.

$^1\text{H-NMR}$ (300 MHz, CDCl_3): δ 9.26(s, 2H), 8.17(d, $J=8.5$ Hz, 4H), 7.69(s, 1H), 7.63(s, 1H), 7.62(d, $J=8.2$ Hz, 4H), 6.71(s, 2H), 3.69(s, 6H), 3.3 2~3.17(m, 2H), 2.50(d, $J=7.5$ Hz, 2H), 2.4 3~2.35(m, 1H), 2.33(d, $J=6.6$ Hz, 2H), 2.2 8~2.18(m, 2H), 2.0 7~1.19(m, 9H), 1.7 3~1.60(m, 4H), 1.57(s, 18H), 1.4 0~1.25(m, 2H). LCMS (ESI) m/z 482.2 $[\text{M} + \text{H}]^+$; HRMS calcd for $\text{C}_{26}\text{H}_{31}\text{N}_3\text{O}_4\text{S}$ $[\text{M} + \text{H}]^+$ 482.2114, found 482.2258

Methyl 2-(4-(4-(4-aminophenyl)thieno[3,2-*d*]pyrimidin-7-yl)cyclohexyl)acetate (12)

To a solution of **11** (280 mg, 0.58 mmol) in dichloromethane (5 mL) was added 0.6 mL of trifluoroacetic acid. The mixture was stirred at room temperature for 12 h. Then the reaction mixture was concentrated to a residue that was partitioned between dichloromethane and saturated aqueous sodium bicarbonate. The organic layer was separated from the aqueous layer, washed with brine, dried over anhydrous magnesium sulphate, and then concentrated to afford 190 mg of the title compound.

$^1\text{H-NMR}$ (300 MHz, $\text{DMSO-}d_6$): δ 9.08(s, 2H), 8.13(s, 1H), 8.04(s, 1H), 8.01(d, $J=8.6$ Hz, 4H), 6.76(d, $J=8.6$ Hz, 4H), 5.90(s, 4H), 3.60(s, 6H), 3.3 0~3.10(m, 2H), 2.48(d, 2H), 2.28(d, $J=6.5$ Hz, 2H), 2.2 5~2.13(m, 1H), 2.2 8~2.16(m, 3H), 2.1 0~1.98(m, 2H), 1.9 0~1.46(m, 14H), 1.3 0~1.10(m, 2H).

Methyl 2-(4-(4-(4-(3-(3-chlorophenyl)ureido)phenyl)thieno[3,2-*d*]pyrimidin-7-yl)cyclohexyl)acetate (13)

To a solution of **12** (3.1 g, 8.13 mmol) in anhydrous tetrahydrofuran (60 mL) was added 3-chlorophenyl isocyanate (1.37 g, 8.92 mmol). The mixture was stirred at room temperature for 18 h. The mixture was concentrated in part and diluted with diethyl ether to give a precipitate, which was filtered to afford 4.06 g of a light-yellow title compound.

$^1\text{H-NMR}$ (300 MHz, $\text{DMSO-}d_6$): δ 9.21(s, 2H), 9.16(s, 2H), 9.03(s, 2H), 8.24(s, 1H), 8.2 1~8.15(m, 5H), 7.7 4~7.71(m, 6H), 7.4 0~7.29(m, 4H), 7.1 0~7.00(m, 2H), 3.61(s, 6H), 3.3 2~3.04(m, 2H), 2.46(d, 2H), 2.29(d, $J=6.5$ Hz, 2H), 2.2 2~2.14(m, 1H), 2.2 1~2.01(m, 2H), 1.8 9~1.49(m, 14H), 1.3 0~1.11(m, 2H). LCMS (ESI) m/z 535.2 $[\text{M} + \text{H}]^+$; HRMS calcd for $\text{C}_{28}\text{H}_{27}\text{ClN}_4\text{O}_3\text{S}$ $[\text{M} + \text{H}]^+$ 535.1571, found 535.1793

Methyl cis-2-(4-(4-(4-(3-(3-chlorophenyl)ureido)phenyl)thieno[3,2-*d*]pyrimidin-7-yl)cyclohexyl)acetate (15a)

13 (150 mg, 0.28 mmol) was added to ethyl acetate (2 mL) and stirred at 70 °C for 12 h, and then cooled to room temperature to give a solid. The solid (**15b**, 72 mg) was filtered, and then the filtrate was concentrated and the residue was purified by silica gel column chromatography to give 76 mg of the yellow title compound **15a**.

$^1\text{H-NMR}$ (300 MHz, $\text{DMSO-}d_6$): δ 9.23(s, 1H), 9.17(s, 1H), 9.04(s, 1H), 8.25(s, 1H), 8.19(d, $J=8.8$ Hz, 2H), 7.7 5~7.72(m, 3H), 7.3 3~7.31(m, 2H), 7.0 7~7.03(m, 1H), 3.61(s, 3H), 3.3 1~3.18(m, 1H), 2.52(d, 2H), 2.2 8~2.14(m, 1H), 1.8 9~1.49(m, 8H). LCMS (ESI) m/z 535.2 $[\text{M} + \text{H}]^+$; HRMS calcd for $\text{C}_{28}\text{H}_{27}\text{ClN}_4\text{O}_3\text{S}$ $[\text{M} + \text{H}]^+$ 535.1571, found 535.1793

Methyl trans-2-(4-(4-(4-(3-(3-chlorophenyl)ureido)phenyl)thieno[3,2-*d*]pyrimidin-7-yl)cyclohexyl)acetate (15b)

$^1\text{H-NMR}$ (300 MHz, $\text{DMSO-}d_6$): δ 9.23(s, 1H), 9.23(s, 1H), 9.16(s, 1H), 9.03(s, 1H), 8.19(d, $J=8.8$ Hz, 2H), 8.16(s, 1H), 7.7 5~7.72(m, 3H), 7.3 6~7.29(m, 2H), 7.0 7~7.03(m, 1H), 3.61(s, 3H), 3.11(t, $J=11.9$ Hz, 1H), 2.30(d, $J=6.5$ Hz, 2H), 2.1 3~2.01(m, 2H), 1.9 0~1.72(m, 3H), 1.6 8~1.50(m, 2H), 1.2 9~1.11(m, 2H). LCMS (ESI) m/z 535.2 $[\text{M} + \text{H}]^+$; HRMS calcd for $\text{C}_{28}\text{H}_{27}\text{ClN}_4\text{O}_3\text{S}$ $[\text{M} + \text{H}]^+$ 535.1571, found 535.1793

cis-2-(4-(4-(4-(3-(3-chlorophenyl)ureido)phenyl)thieno[3,2-*d*]pyrimidin-7-yl)cyclohexyl)acetic acid (16a)

To a solution of **15a** (7.8 g, 14.58 mmol) in tetrahydrofuran/methanol/water (120 mL, 1:1:1) was added 1.17 g of sodium hydroxide (29.25 mmol), and the mixture was stirred. The reaction mixture was acidified with 1 N HCl (pH was adjusted to between 5 and 6) to give a solid. The solid was filtered, and washed with water to afford **16a** quantitatively.

$^1\text{H-NMR}$ (300 MHz, $\text{DMSO-}d_6$): δ 9.28(s, 1H), 9.23(s, 1H), 9.16(s, 1H), 8.24(s, 1H), 8.19(d, $J=8.8$ Hz, 2H), 7.7 5~7.72(m, 3H), 7.3 3~7.31(m, 2H), 7.1 0~7.00(m, 1H), 3.3 2~3.20(m, 1H), 2.39(d, $J=7.5$ Hz, 2H), 2.2 8~2.14(m, 1H), 1.9 0~1.50(m, 8H). $^{13}\text{C-NMR}$ (150 MHz, $\text{DMSO-}d_6$): δ 174.08, 160.01, 158.32, 154.04, 152.20, 142.37, 142.10, 141.00, 133.20, 131.36, 130.43, 129.97, 129.20, 127.20, 121.70, 118.21, 117.66, 116.75, 37.03, 35.51, 30.03, 29.31, 27.18. LCMS (ESI) m/z 521.1 $[\text{M} + \text{H}]^+$; HRMS calcd for $\text{C}_{27}\text{H}_{25}\text{ClN}_4\text{O}_3\text{S}$ $[\text{M} + \text{H}]^+$ 521.1414, found 521.1441

trans-2-(4-(4-(4-(3-(3-chlorophenyl)ureido)phenyl)thieno[3,2-*d*]pyrimidin-7-yl)cyclohexyl)acetic acid (16b)

16b was obtained from the procedure described for 16a. $^1\text{H-NMR}$ (300 MHz, $\text{DMSO-}d_6$): δ 12.04(s, 1H), 9.29(s, 1H), 9.23(s, 1H), 9.16(s, 1H), 8.18(d, $J=9.0$ Hz, 2H), 8.15(s, 1H), 7.7 5~7.72(m, 3H), 7.3 6~7.29(m, 2H), 7.0 7~7.02(m, 1H), 3.11(t, $J=12.1$, 1H), 2.19(d, $J=6.7$ Hz, 2H), 2.1 3~2.01(m, 2H), 1.9 0~1.72(m, 3H), 1.6 8~1.50(m, 2H), 1.2 9~1.11(m, 2H). $^{13}\text{C-NMR}$ (150 MHz, $\text{DMSO-}d_6$): δ 173.90, 159.93, 158.35, 154.10, 152.22, 142.36, 141.05, 133.19, 130.81, 130.41, 129.97, 129.17, 127.27, 121.68, 118.25, 117.70, 116.79, 41.60, 36.15, 34.13, 32.42, 32.05. LCMS (ESI) m/z 521.1 $[\text{M} + \text{H}]^+$; HRMS calcd for $\text{C}_{27}\text{H}_{25}\text{ClN}_4\text{O}_3\text{S}$ $[\text{M} + \text{H}]^+$ 521.1414, found 521.1441

Sodium cis-2-(4-(4-(4-(3-(3-chlorophenyl)ureido)phenyl)thieno[3,2-d]pyrimidin-7-yl)cyclohexyl)acetate (17a)

To a solution of **16a** (7.6 g, 14.59 mmol) in 100 mL of methanol was added 14 mL of a 1 N sodium hydroxide. The resulting mixture was stirred at room temperature for 2 h. The solvent was removed to give 8.3 g of the yellow title compound **17a**.

¹H-NMR (300 MHz, DMSO-*d*₆): δ 12.50(s, 1H), 12.37(s, 1H), 9.21(s, 1H), 8.23(s, 1H), 8.17(d, *J* = 8.8 Hz, 2H), 7.75 ~ 7.72(m, 3H), 7.56(d, *J* = 9.0 Hz, 1H), 7.27(t, *J* = 8.1 Hz, 1H), 6.96(d, *J* = 7.9 Hz, 1H), 3.32 ~ 3.18(m, 1H), 2.40 ~ 2.20(m, 3H), 2.00 ~ 1.60(m, 8H). ¹³C-NMR (150 MHz, DMSO-*d*₆): δ 178.28, 160.00, 158.50, 154.04, 153.53, 144.38, 142.88, 142.70, 132.90, 130.91, 130.04, 128.93, 128.77, 126.97, 120.44, 117.95, 117.40, 116.55, 41.40, 39.08, 30.92, 30.03, 27.70. LCMS (ESI) *m/z* 521.1 [M+H]⁺; HRMS calcd for C₂₇H₂₅ClN₄O₃S [M+H]⁺ 521.1414, found 521.1441 (as free base)

Sodium trans-2-(4-(4-(4-(3-(3-chlorophenyl)ureido)phenyl)thieno[3,2-d]pyrimidin-7-yl)cyclohexyl)acetate (17b)

¹H-NMR (300 MHz, DMSO-*d*₆): δ 12.27(s, 1H), 12.25(s, 1H), 9.18(s, 1H), 8.17(d, *J* = 8.9 Hz, 2H), 7.99(s, 1H), 7.89(d, *J* = 8.9 Hz, 2H), 7.83(s, 1H), 7.56(d, *J* = 9.3 Hz, 1H), 7.27(t, *J* = 8.1 Hz, 1H), 6.96(d, *J* = 8.0 Hz, 1H), 3.11(t, *J* = 11.6, 1H), 2.10 ~ 1.83(m, 2H), 1.68 ~ 1.46(m, 2H), 1.29 ~ 1.11(m, 2H). ¹³C-NMR (150 MHz, DMSO-*d*₆): δ 178.21, 159.84, 158.38, 154.07, 153.42, 144.40, 142.93, 142.83, 132.90, 130.28, 130.05, 128.94, 128.60, 126.87, 120.48, 117.80, 117.32, 116.49, 46.16, 36.07, 35.92, 33.08, 32.68. LCMS (ESI) *m/z* 521.1 [M+H]⁺; HRMS calcd for C₂₇H₂₅ClN₄O₃S [M+H]⁺ 521.1414, found 521.1441 (as free base)

DGAT-1 inhibition assay (IC₅₀)

The activity of DGAT-1 inhibitors *in vitro* was evaluated by using a human recombinant DGAT1 enzyme expressed in insect cells (SF9 cells). SF9 cells were homogenised by washing them with DPBS (Dulbecco's phosphate-buffered saline) and then suspending cell pellets with a tris buffer (250 mM sucrose; 10 mM Tris-HCl [pH 7.4]; proteinase inhibitor). The resulting mixture was centrifugally separated at 10,000 × *g* for 30 min to remove the cell debris remaining in the lower layer thereof, and was centrifugally separated at 100,000 × *g* for 60 min to obtain a microsomal membrane. Further, membrane fractions were resuspended by the tris buffer, and then stored at -80 °C.

The activity of DGAT1 was measured according to the reported method²⁰. Specifically, 0.0001 – 10 μM (final concentration, FC) of the test compounds were cultured at room temperature (25 °C) for 15 min with a 10 μM of SF9 microsomal protein solution and 100 mM of MgCl₂ solution, and were then further cultured at room temperature (25 °C) for 30 min after the addition of 100 μM (FC in 12.5% EtOH) of 1,2-dioleoyl-sn-glycerol and 30 μM (final conc.) of ¹⁴C-oleyl coenzyme A. The reaction was completed by the addition of 300 μL of a mixed solution of 2-propanol/heptane (7:1), and radioactive triglyceride was separated from an organic solvent layer by using 200 μL of heptane and 200 μL of a 0.1 M carbonate buffer (pH 9.5). The amount of triglyceride was measured by liquid scintillography (Perkin Elmer, USA) after mixing with an organic solvent and an equivalent amount of scintillation solvent (MicroScint-O, Perkin Elmer, USA). The effects of inhibiting DGAT1 were calculated as percent in comparison with a control material.

Oral lipid tolerance test (OLTT)**Mouse**

Male, Institute of Cancer Research (ICR) mice were obtained from OrientBio Inc. (Republic of Korea). ICR mice (8-weeks old, *n* = 5/group) fasted 16 h, received 5 mL/kg corn oil via oral administration (p.o.) 30 min after compound administration. Plasma was collected at different time points (0, 1, 2, and 4 h).

Dog

Beagle dogs (9 months old, *n* = 2/group) were obtained from Woojung Bio Inc. (Republic of Korea) were fasted for 16 h and received heavy cream (2.7 mL/kg), glucose (1 g/kg), water (5.3 mL/kg), and acetaminophen (20 mg/kg p.o.) 1 h after compound administration. Blood samples were collected at -0.5, 0, 1, 2, and 4 h.

Statistical analysis



Statistical analysis was performed using one-way ANOVA, followed by Dunnett's multiple comparison test using Prism 6.0 (GraphPad, USA). The Kruskal-Wallis test was applied when data did not pass the normality test.

Results and discussion

We found that thieno[3,2-*d*]pyrimidine could be a core scaffold connecting an aryl moiety at one end to a cyclo-aliphatic carboxylic acid group at the other. Synthetic schemes for a series of thieno[3,2-*d*]pyrimidine derivatives are outlined in Schemes 1 and 2.

Desired compounds **14a–14l** were synthesised from commercially available 7-bromo-4-chlorothieno[3,2-*d*]pyrimidine (**6**), as shown in Scheme 1. Consecutive Suzuki coupling reactions gave **8** and **10**. Compound **9** was prepared using the reported method¹⁹. Hydrogenation of **10**, followed by de-protection of the Boc group with trifluoroacetic acid afforded the key intermediate **12**. The aniline **12** was converted to amides **14a–14h** or ureas **14i–14l** by coupling with acid chlorides or aryl isocyanates, respectively, followed by hydrolysis with sodium hydroxide or lithium hydroxide.


The activities of synthesised compounds were evaluated using SF9 insect cells expressing human DGAT-1²². The IC₅₀ values are summarised in Table 1. A potent DGAT-1 inhibitor, **LCQ-908** (**2** or pradigastat) was used as a positive control. To optimise the alkyl chain length of the acid moiety, compound **14b** (*n* = 1) was more potent than short chain **14a** (*n* = 0) and long chain **14c** (*n* = 2). The calculated lowest energy conformation model of **14c** provided that the distance between the terminal carboxylic acid and NH of urea was over 16 Å, which may result in reduced activity. **14a** exhibited a loss of activity, which suggested that the terminal carboxylic acid should be placed one-carbon away from cyclohexane. Next, structure-activity relationships for the aryl moiety on the left side were investigated, with derivatives bearing chain lengths the same as that of **14b**. 5-chloro-2-nitro phenyl (**14d**), 2-trifluoromethylpyridinyl (**14f**), 4-chloropyridinyl (**14k**), and 5-bromopyridinyl (**14l**) derivatives had no activity (IC₅₀ > 1 μM), while **14b**, **14c**, **14e**, **14h**, and **14j** had good activity (IC₅₀ values of 0.3 μM–0.4 μM). Compounds **14g** and **14i** were equipotent to the known compound **2**. The most potent compound, **14i**, was subjected to further investigation. *Cis* and *trans* isomers of **14i** were separated to determine the activity and properties of each isomer. As shown in Scheme 2, the racemic mixture **13** was conveniently separated






into *cis*-isomer **15a** and *trans*-isomers **15b** by the treatment with ethyl acetate. **15a** and **15b** exhibited greatly different solubility for ethyl acetate, and were soluble and insoluble for ethyl acetate, respectively. Hydrolysis of **15a** and **15b** afforded *cis* isomer **17a** and *trans* isomer **17b**, respectively.

Interestingly, the isomers **17a** and **17b** were more potent than mixture **14i**, and even compound **2**, in SF9 cells (Table 2).

However, pharmacokinetic studies demonstrated that *cis*-isomer **17a** had a much better profile than *trans*-isomer **17b** (Table 3). **17a** had a shorter half-life (1.2 h), but had much better bioavailability, compared to **17b**. In enzymatic assays, **17a** had an IC₅₀ of 61 nM for DGAT-1 and displayed high off-target selectivity against DGAT-2, acyl-coenzyme A (CoA):cholesterol acyltransferases (ACAT1 and ACAT2) (Table 2). ACATs have sequence homology to



Compound	n	R ₁	DGAT-1 IC ₅₀ (μM) ^a
2			0.157
14a	0		>1
14b	1		0.276
14c	2		0.409
14d	1		>1
14e	1		0.326
14f	1		>1
14g	1		0.152
14h	1		0.398
14i	1		0.121
14j	1		0.351
14k	1		>1,000
14l	1		>1,000

IC ₅₀ (nM)					
Compound	DGAT1(SF9)	hDGAT1	hDGAT2	hACAT1	hACAT2
2	157	57	>10,000	>10,000	>10,000
17a	74	61	>10,000	>10,000	>10,000
17b	89	—	—	—	—

Compounds	17a	17b
AUC _{0~24} (ng·h/mL)	861.2	233.7
C _{max} (ng/mL)	479.3	74.8
T _{1/2} (h)	1.2	5.2
Bioavailability (%)	19	0.7

Parameters	AUC 0~24 (ng·h/mL)	<i>T</i> 1/2 (h)	Cl (L/hr/kg)	Bioavailability (%)
Rat ^a	18,594.5 ± 6764.2	3.0 ± 0.4	0.5 ± 0.2	30
Dog ^b	8243.0 ± 2296.3	3.6 ± 0.7	0.4 ± 0.1	53

No	Microsomal stability, (%) ^a				CYPs enzyme inhibition, IC ₅₀ (μM) ^b				
	Human	Dog	Rat	Mouse	CYP3A4	CYP1A2	CYP2C9	CYP2C19	CYP2D6
17a	94	82	87	82	16.2	10.6	2.9	>20	8.7

^bData were analysed by a fluorescence detection method.




Figure 3. Effect of **17a** in the oral lipid tolerance test ($n=5$, $***p<.001$). Serum TG (or TAG) concentration was measured before and 1, 2, and 4 h after oral administration of corn oil in ICR mice treated with **17a** (3 mg/kg) or **2** (1 mg/kg). Vehicle for **2**: 0.5% methylcellulose/0.5% Tween80 in distilled water, vehicle for **17a**: 0.5% Tween80 in distilled water.




Figure 4. Effect of **17a** in a canine oral lipid tolerance test ($n=2$, $*p<.05$; $***p<.001$). The dog was treated with **17a** (po. 1 mg/kg) or **2** (po. 1 mg/kg) before oral administration of corn oil. Vehicle for **2**: 0.5% methylcellulose/0.5% Tween80 in distilled water, vehicle for **17a**: 0.5% Tween80 in distilled water.

DGAT-1 and play essential roles in cholesterol homeostasis²³. **17b** was not explored in the enzymatic assays due to its poor pharmacokinetic profile.

Considering potency, selectivity, and pharmacokinetic profiles, **17a** was investigated for further pharmacokinetic properties in four species, and results are summarised in Tables 4 and 5. **17a** exhibited low to moderate clearance and acceptable oral bioavailability in rat and dog.

17a exhibited durable metabolic stabilities, as shown in Table 5. In particular, **17a** was metabolically stable in four species: human, dog, rat, and mouse. Further evaluation of **17a** was carried out for inhibition of clinically relevant cytochrome 450 (CYP) isoforms (3A4, 1A2, 2C9, 2C19, 2D6). No significant inhibition by **17a** was observed (Table 5). Thus, **17a** would be very unlikely to affect the pharmacokinetics of other drugs.

To determine *in vivo* efficacy, we evaluated the activity of **17a** against serum TAG level induced by the oral administration of corn oil (oral lipid tolerance test, OLTT; Figures 3 and 4), since intestinal targeted DGAT-1 inhibition results in a reduced serum TAG level¹⁴. **17a** was orally administered to ICR mice at 3 mg/kg or to dogs at 1 mg/kg before administration of corn oil. As shown in Figure 3, **17a** showed significant activity, as potent as compound **2**, in reducing plasma TAG level.

In addition, tissue distribution of **17a** was investigated. **17a** was orally administered to mice at 30 mg/kg, and **2** was administered as a positive control (Figure 5). The concentration levels of **17a** in the liver and small intestine were much higher than in other tissues, indicating that liver and small intestine are the main target organs of **17a**, while **2** showed much high concentrations in the liver and large intestine. Analysis of tissue-to-plasma ratios indicated that **17a** had favourable distributions in the liver and small intestine. Significant activity of **17a** in the OLTT appeared to result from high concentration in the small intestine, even though bioavailability of **17a** was not great in mice. This result could be proof of a pharmacokinetic–pharmacodynamic correlation.

Conclusion

We found that a novel series of thieno[3,2-*d*]pyrimidine derivatives had potent DGAT-1 inhibitory activity. A representative compound, *cis*-isomer **17a** showed potent DGAT-1 inhibitory activity, metabolic stability in four species, an acceptable pharmacokinetic profile in rodents and dogs, and a significant reduction of TAG in the OLTT in mice and dogs. In a tissue-distribution study, **17a** was mainly distributed to the liver and small intestine. Therefore, **17a**




Figure 5. Tissue distribution of **17a** in mice. **17a** and **2** were orally administered to ICR mice at 30 mg/kg ($n=3$). (a) AUC values of **17a** and **2** in indicated tissues. Each bar shows AUC obtained from concentrations measured at 0.5 h, 1 h, 2 h, 4 h, and 24 h after dosing. Data represent mean value. (b) Tissue-to-plasma (T/P) ratio of **17a** and **2**. S.I.: small intestine, L.I.: large intestine.

could be a candidate with considerable potential and deserves for further investigation.

Disclosure statement

No potential conflict of interest was reported by the authors.

Funding

This research was supported by the Advanced Research Centre Programme (2015R1A5 A1008958) funded by the Korean Government.

References

1. Kusminski CM, Bickel PE, Scherer PE. Targeting adipose tissue in the treatment of obesity-associated diabetes. *Nat Rev Drug Discov* 2016;15:639–60.
2. Subauste A, Burant CF. Dgat: novel therapeutic target for obesity and type 2 diabetes mellitus. *Curr Drug Targets Immune Endocr Metabol Disord* 2003;3:263–70.
3. Capeau J. Insulin resistance and steatosis in humans. *Diabetes Metab* 2008;34:649–57.
4. Kennedy EP. Metabolism of lipides. *Annu Rev Biochem* 1957;26:119–48.
5. Yen CL, Stone SJ, Koliwad S, et al. Thematic review series: glycerolipids. Dgat enzymes and triacylglycerol biosynthesis. *J Lipid Res* 2008;49:2283–301.
6. Bhatt-Wessel B, Jordan TW, Miller JH, Peng L. Role of dgat enzymes in triacylglycerol metabolism. *Arch Biochem Biophys* 2018;655:1–11.
7. Smith SJ, Cases S, Jensen DR, et al. Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking dgat. *Nat Genet* 2000;25:87–90.
8. Stone SJ, Myers HM, Watkins SM, et al. Lipopenia and skin barrier abnormalities in dgat2-deficient mice. *J Biol Chem* 2004;279:11767–76.
9. Birch AM, Buckett LK, Turnbull AV. Dgat1 inhibitors as anti-obesity and anti-diabetic agents. *Curr Opin Drug Discov Devel* 2010;13:489–96.
10. King AJ, Judd AS, Souers AJ. Inhibitors of diacylglycerol acyltransferase: a review of 2008 patents. *Expert Opin Ther Pat* 2010;20:19–29.
11. Motiwala H, Kandre S, Birar V, et al. Exploration of pyridine containing heteroaryl analogs of biaryl ureas as dgat1 inhibitors. *Bioorg Med Chem Lett* 2011;21:5812–7.
12. McCoull W, Addie MS, Birch AM, et al. Identification, optimisation and in vivo evaluation of oxadiazole dgat-1 inhibitors for the treatment of obesity and diabetes. *Bioorg Med Chem Lett* 2012;22:3873–8.
13. Meyers C, Gaudet D, Tremblay K, et al. The dgat1 inhibitor lcq908 decreases triglyceride levels in patients with the familial chylomicronemia syndrome. *J Clin Lipidol* 2012;6:266–7.
14. King AJ, Segreti JA, Larson KJ, et al. Diacylglycerol acyltransferase 1 inhibition lowers serum triglycerides in the Zucker fatty rat and the hyperlipidemic hamster. *J Pharmacol Exp Ther* 2009;330:526–31.
15. Zhao G, Souers AJ, Voorbach M, et al. Validation of diacylglycerolacyltransferase 1 as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor. *J Med Chem* 2008;51:380–3.
16. Qian Y, Wertheimer SJ, Ahmad M, et al. Discovery of orally active carboxylic acid derivatives of 2-phenyl-5-trifluoromethyl-oxazole-4-carboxamide as potent diacylglycerol acyltransferase-1 inhibitors for the potential treatment of obesity and diabetes. *J Med Chem* 2011;54:2433–46.
17. Harrison TJ, Bauer D, Berdichevsky A, et al. Successful strategies for mitigation of a preclinical signal for phototoxicity in a dgat1 inhibitor. *ACS Med Chem Lett* 2019;10:1128–33.
18. Yu Y, Wu Z, Shi Z-C, et al. Accelerating the discovery of dgat1 inhibitors through the application of parallel medicinal chemistry (pmc). *Bioorg Med Chem Lett* 2019;29:1380–5.
19. Nakajima K, Chatelain R, Clairmont KB, et al. Discovery of an orally bioavailable benzimidazole diacylglycerol acyltransferase 1 (dgat1) inhibitor that suppresses body weight gain in diet-induced obese dogs and postprandial triglycerides in humans. *J Med Chem* 2017;60:4657–64.
20. Devani MB, Shishoo CJ, Pathak US, et al. Synthesis of 3-substituted thieno [2, 3-d] pyrimidin-4(3h)-one-2-mercaptoacetic acids and their ethyl esters for pharmacological screening. *J Pharm Sci* 1976;65:660–4.
21. Dow RL, Munchhof MJ. Preparation of substituted dihydropyrimidooxazepine derivatives for use as antiobesity agents. In: Preparation of substituted dihydropyrimidooxazepine derivatives for use as antiobesity agents; 20080722; WO: Pfizer Products Inc.; 2009.
22. Birch AM, Birtles S, Buckett LK, et al. Discovery of a potent, selective, and orally efficacious pyrimidinooxazinyl bicycloc-taneacetic acid diacylglycerol acyltransferase-1 inhibitor. *J Med Chem* 2009;52:1558–68.
23. Pramfalk C, Eriksson M, Parini P. Cholesteryl esters and acat. *Eur J Lipid Sci Technol* 2012;114:624–33.